1202055-32-0 Usage
General Description
NMS-P715 is a small molecule inhibitor that acts as a selective and potent allosteric inhibitor of the protein phosphatase 2A (PP2A) enzyme. NMS-P715 has shown promising anti-cancer effects in preclinical studies, as it blocks the growth and survival of cancer cells by inhibiting PP2A activity. NMS-P715 has also been found to enhance the anti-tumor effects of other chemotherapy drugs and to overcome drug resistance in cancer cells. Additionally, it has demonstrated a good safety profile and low toxicity in animal studies, making it a potential candidate for further development as a cancer therapy.
Check Digit Verification of cas no
The CAS Registry Mumber 1202055-32-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,0,2,0,5 and 5 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1202055-32:
(9*1)+(8*2)+(7*0)+(6*2)+(5*0)+(4*5)+(3*5)+(2*3)+(1*2)=80
80 % 10 = 0
So 1202055-32-0 is a valid CAS Registry Number.
1202055-32-0Relevant articles and documents
Synthesis and SAR of new pyrazolo[4,3-h]quinazoline-3-carboxamide derivatives as potent and selective MPS1 kinase inhibitors
Caldarelli, Marina,Angiolini, Mauro,Disingrini, Teresa,Donati, Daniele,Guanci, Marco,Nuvoloni, Stefano,Posteri, Helena,Quartieri, Francesca,Silvagni, Marco,Colombo, Riccardo
, p. 4507 - 4511 (2011/09/12)
The synthesis and SAR of a series of novel pyrazolo-quinazolines as potent and selective MPS1 inhibitors are reported. We describe the optimization of the initial hit, identified by screening the internal library collection, into an orally available, potent and selective MPS1 inhibitor.
